View ValuationGeneFerm Biotechnology 将来の成長Future 基準チェック /06現在、 GeneFerm Biotechnologyの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Personal Products 収益成長15.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesUpcoming Dividend • Jul 07Upcoming dividend of NT$0.70 per shareEligible shareholders must have bought the stock before 14 July 2026. Payment date: 30 July 2026. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.0%. Lower than top quartile of Taiwanese dividend payers (4.9%). Lower than average of industry peers (5.6%).Reported Earnings • May 09First quarter 2026 earnings released: NT$0.16 loss per share (vs NT$0.16 profit in 1Q 2025)First quarter 2026 results: NT$0.16 loss per share (down from NT$0.16 profit in 1Q 2025). Revenue: NT$153.2m (down 7.9% from 1Q 2025). Net loss: NT$6.69m (down 203% from profit in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 48 percentage points per year, which is a significant difference in performance.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 23%After last week's 23% share price gain to NT$41.50, the stock trades at a trailing P/E ratio of 59.6x. Average trailing P/E is 16x in the Personal Products industry in Taiwan. Total loss to shareholders of 56% over the past three years.New Risk • Apr 06New minor risk - Dividend sustainabilityThe dividend is not well covered by earnings. Payout ratio: 101% Dividend yield: 1.7% This is considered a minor risk. Companies that pay out too much of their earnings are at risk of having to reduce or cut their dividend in future. If earnings growth slows or earnings fall, then there may not be enough earnings to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. However, this risk is mitigated by the fact the dividend is covered by cash flows. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 14% per year over the past 5 years. Minor Risks Dividend is not well covered by earnings (101% payout ratio). Market cap is less than US$100m (NT$1.69b market cap, or US$52.7m).Reported Earnings • Mar 06Full year 2025 earnings released: EPS: NT$0.70 (vs NT$0.54 loss in FY 2024)Full year 2025 results: EPS: NT$0.70 (up from NT$0.54 loss in FY 2024). Revenue: NT$677.1m (up 30% from FY 2024). Net income: NT$28.9m (up NT$51.4m from FY 2024). Profit margin: 4.3% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance.お知らせ • Mar 06GeneFerm Biotechnology Co., Ltd., Annual General Meeting, Jun 17, 2026GeneFerm Biotechnology Co., Ltd., Annual General Meeting, Jun 17, 2026. Location: no,3, ta li 2nd rd., shanhua district, tainan city TaiwanReported Earnings • Nov 07Third quarter 2025 earnings released: EPS: NT$0.14 (vs NT$0.27 loss in 3Q 2024)Third quarter 2025 results: EPS: NT$0.14 (up from NT$0.27 loss in 3Q 2024). Revenue: NT$165.6m (up 26% from 3Q 2024). Net income: NT$5.65m (up NT$16.9m from 3Q 2024). Profit margin: 3.4% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.New Risk • Oct 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Market cap is less than US$100m (NT$2.16b market cap, or US$70.7m).Reported Earnings • Aug 09Second quarter 2025 earnings released: EPS: NT$0.02 (vs NT$0.14 loss in 2Q 2024)Second quarter 2025 results: EPS: NT$0.02 (up from NT$0.14 loss in 2Q 2024). Revenue: NT$167.9m (up 45% from 2Q 2024). Net income: NT$898.0k (up NT$6.93m from 2Q 2024). Profit margin: 0.5% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance.Reported Earnings • May 09First quarter 2025 earnings released: EPS: NT$0.16 (vs NT$0.20 loss in 1Q 2024)First quarter 2025 results: EPS: NT$0.16 (up from NT$0.20 loss in 1Q 2024). Revenue: NT$166.4m (up 41% from 1Q 2024). Net income: NT$6.47m (up NT$14.8m from 1Q 2024). Profit margin: 3.9% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.Reported Earnings • Mar 15Full year 2024 earnings released: NT$0.54 loss per share (vs NT$3.01 profit in FY 2023)Full year 2024 results: NT$0.54 loss per share (down from NT$3.01 profit in FY 2023). Revenue: NT$521.2m (down 34% from FY 2023). Net loss: NT$22.5m (down 118% from profit in FY 2023). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.お知らせ • Mar 10GeneFerm Biotechnology Co., Ltd., Annual General Meeting, Jun 19, 2025GeneFerm Biotechnology Co., Ltd., Annual General Meeting, Jun 19, 2025. Location: no,3, ta li 2nd rd., shanhua district, tainan city TaiwanNew Risk • Mar 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Dividend per share is over 18x cash flows per share. Minor Risks Share price has been volatile over the past 3 months (6.0% average weekly change). Market cap is less than US$100m (NT$2.47b market cap, or US$74.9m).Reported Earnings • Nov 18Third quarter 2024 earnings released: NT$0.27 loss per share (vs NT$0.82 profit in 3Q 2023)Third quarter 2024 results: NT$0.27 loss per share (down from NT$0.82 profit in 3Q 2023). Revenue: NT$131.9m (down 32% from 3Q 2023). Net loss: NT$11.2m (down 133% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.New Risk • Aug 17New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 5.4% Last year net profit margin: 16% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 250% Cash payout ratio: 111% Minor Risks Profit margins are more than 30% lower than last year (5.4% net profit margin). Market cap is less than US$100m (NT$2.12b market cap, or US$65.7m).Upcoming Dividend • Jul 03Upcoming dividend of NT$2.00 per shareEligible shareholders must have bought the stock before 10 July 2024. Payment date: 31 July 2024. Payout ratio is on the higher end at 97%, however this is supported by cash flows. Trailing yield: 3.0%. Lower than top quartile of Taiwanese dividend payers (4.2%). Lower than average of industry peers (4.3%).Valuation Update With 7 Day Price Move • May 21Investor sentiment improves as stock rises 19%After last week's 19% share price gain to NT$66.20, the stock trades at a trailing P/E ratio of 32x. Average trailing P/E is 19x in the Personal Products industry in Taiwan. Total returns to shareholders of 112% over the past three years.Reported Earnings • May 19First quarter 2024 earnings released: NT$0.20 loss per share (vs NT$0.73 profit in 1Q 2023)First quarter 2024 results: NT$0.20 loss per share (down from NT$0.73 profit in 1Q 2023). Revenue: NT$118.4m (down 36% from 1Q 2023). Net loss: NT$8.31m (down 127% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.New Risk • Apr 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.1% average weekly change). Market cap is less than US$100m (NT$2.82b market cap, or US$88.2m).Valuation Update With 7 Day Price Move • Mar 28Investor sentiment improves as stock rises 22%After last week's 22% share price gain to NT$66.90, the stock trades at a trailing P/E ratio of 22.3x. Average trailing P/E is 20x in the Personal Products industry in Taiwan. Total returns to shareholders of 114% over the past three years.Reported Earnings • Mar 17Full year 2023 earnings released: EPS: NT$3.01 (vs NT$2.26 in FY 2022)Full year 2023 results: EPS: NT$3.01 (up from NT$2.26 in FY 2022). Revenue: NT$793.8m (up 25% from FY 2022). Net income: NT$124.6m (up 33% from FY 2022). Profit margin: 16% (up from 15% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 08GeneFerm Biotechnology Co., Ltd., Annual General Meeting, Jun 19, 2024GeneFerm Biotechnology Co., Ltd., Annual General Meeting, Jun 19, 2024.New Risk • Oct 18New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.06b (US$94.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.Reported Earnings • Aug 11Second quarter 2023 earnings released: EPS: NT$1.13 (vs NT$0.72 in 2Q 2022)Second quarter 2023 results: EPS: NT$1.13 (up from NT$0.72 in 2Q 2022). Revenue: NT$231.9m (up 51% from 2Q 2022). Net income: NT$46.8m (up 56% from 2Q 2022). Profit margin: 20% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has only increased by 56% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Jun 22Upcoming dividend of NT$1.50 per share at 1.4% yieldEligible shareholders must have bought the stock before 29 June 2023. Payment date: 27 July 2023. Payout ratio is a comfortable 60% but the company is not cash flow positive. Trailing yield: 1.4%. Lower than top quartile of Taiwanese dividend payers (5.5%). Lower than average of industry peers (2.8%).Valuation Update With 7 Day Price Move • Jun 14Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to NT$112, the stock trades at a trailing P/E ratio of 44.7x. Average trailing P/E is 26x in the Personal Products industry in Taiwan. Total returns to shareholders of 371% over the past three years.Valuation Update With 7 Day Price Move • May 30Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to NT$127, the stock trades at a trailing P/E ratio of 56.1x. Average trailing P/E is 29x in the Personal Products industry in Taiwan. Total returns to shareholders of 394% over the past three years.Valuation Update With 7 Day Price Move • May 05Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$139, the stock trades at a trailing P/E ratio of 61.7x. Average trailing P/E is 34x in the Personal Products industry in Taiwan. Total returns to shareholders of 490% over the past three years.Valuation Update With 7 Day Price Move • Apr 17Investor sentiment improves as stock rises 18%After last week's 18% share price gain to NT$115, the stock trades at a trailing P/E ratio of 51x. Average trailing P/E is 34x in the Personal Products industry in Taiwan. Total returns to shareholders of 381% over the past three years.Reported Earnings • Mar 22Full year 2022 earnings released: EPS: NT$2.26 (vs NT$1.45 in FY 2021)Full year 2022 results: EPS: NT$2.26 (up from NT$1.45 in FY 2021). Revenue: NT$634.0m (up 21% from FY 2021). Net income: NT$93.5m (up 63% from FY 2021). Profit margin: 15% (up from 11% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has only increased by 68% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Mar 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$100.00, the stock trades at a trailing P/E ratio of 44.4x. Average trailing P/E is 28x in the Personal Products industry in Taiwan. Total returns to shareholders of 295% over the past three years.Valuation Update With 7 Day Price Move • Feb 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$82.70, the stock trades at a trailing P/E ratio of 36.7x. Average trailing P/E is 30x in the Personal Products industry in Taiwan. Total returns to shareholders of 215% over the past three years.Valuation Update With 7 Day Price Move • Dec 19Investor sentiment improved over the past weekAfter last week's 17% share price gain to NT$65.60, the stock trades at a trailing P/E ratio of 29.1x. Average trailing P/E is 28x in the Personal Products industry in Taiwan. Total returns to shareholders of 121% over the past three years.Reported Earnings • Nov 13Third quarter 2022 earnings released: EPS: NT$0.61 (vs NT$0.45 in 3Q 2021)Third quarter 2022 results: EPS: NT$0.61 (up from NT$0.45 in 3Q 2021). Revenue: NT$166.1m (up 24% from 3Q 2021). Net income: NT$25.5m (up 40% from 3Q 2021). Profit margin: 15% (up from 14% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Aug 26Investor sentiment improved over the past weekAfter last week's 17% share price gain to NT$54.80, the stock trades at a trailing P/E ratio of 26.4x. Average trailing P/E is 22x in the Personal Products industry in Taiwan. Total returns to shareholders of 73% over the past three years.Upcoming Dividend • Jun 16Upcoming dividend of NT$1.00 per shareEligible shareholders must have bought the stock before 23 June 2022. Payment date: 15 July 2022. Payout ratio is a comfortable 5.1% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of Taiwanese dividend payers (6.0%). Lower than average of industry peers (4.0%).Reported Earnings • May 09First quarter 2022 earnings released: EPS: NT$0.50 (vs NT$0.31 in 1Q 2021)First quarter 2022 results: EPS: NT$0.50 (up from NT$0.31 in 1Q 2021). Revenue: NT$143.9m (up 26% from 1Q 2021). Net income: NT$20.5m (up 81% from 1Q 2021). Profit margin: 14% (up from 10.0% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.Reported Earnings • Nov 11Third quarter 2021 earnings released: EPS NT$0.45 (vs NT$0.15 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: NT$133.9m (up 44% from 3Q 2020). Net income: NT$18.2m (up 340% from 3Q 2020). Profit margin: 14% (up from 4.5% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Oct 12Investor sentiment improved over the past weekAfter last week's 20% share price gain to NT$42.00, the stock trades at a trailing P/E ratio of 53.6x. Average trailing P/E is 15x in the Personal Products industry in Taiwan. Total returns to shareholders of 1.9% over the past three years.Upcoming Dividend • Jul 15Upcoming dividend of NT$0.083 per shareEligible shareholders must have bought the stock before 22 July 2021. Payment date: 12 August 2021. Trailing yield: 0.2%. Lower than top quartile of Taiwanese dividend payers (5.0%). Lower than average of industry peers (3.8%).Reported Earnings • May 09First quarter 2021 earnings released: EPS NT$0.31 (vs NT$0.20 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: NT$113.9m (up 28% from 1Q 2020). Net income: NT$11.3m (up NT$17.0m from 1Q 2020). Profit margin: 10.0% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.分析記事 • Apr 16GeneFerm Biotechnology (GTSM:1796) Takes On Some Risk With Its Use Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Mar 29Full year 2020 earnings released: EPS NT$0.16 (vs NT$0.99 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$368.3m (up 12% from FY 2019). Net income: NT$4.53m (up NT$32.1m from FY 2019). Profit margin: 1.2% (up from net loss in FY 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.分析記事 • Mar 12Will GeneFerm Biotechnology (GTSM:1796) Multiply In Value Going Forward?If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Reported Earnings • Mar 12Full year 2020 earnings released: EPS NT$0.16 (vs NT$0.99 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$368.3m (up 12% from FY 2019). Net income: NT$4.53m (up NT$32.1m from FY 2019). Profit margin: 1.2% (up from net loss in FY 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 97% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.お知らせ • Mar 11GeneFerm Biotechnology Co., Ltd., Annual General Meeting, May 25, 2021GeneFerm Biotechnology Co., Ltd., Annual General Meeting, May 25, 2021.Is New 90 Day High Low • Jan 13New 90-day high: NT$31.80The company is up 57% from its price of NT$20.30 on 16 October 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is down 7.0% over the same period.分析記事 • Dec 21Does GeneFerm Biotechnology (GTSM:1796) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Is New 90 Day High Low • Nov 16New 90-day high: NT$25.50The company is up 7.0% from its price of NT$23.80 on 18 August 2020. The Taiwanese market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is down 15% over the same period.Reported Earnings • Nov 08Third quarter 2020 earnings released: EPS NT$0.14The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$92.9m (up 15% from 3Q 2019). Net income: NT$4.14m (up NT$6.50m from 3Q 2019). Profit margin: 4.5% (up from net loss in 3Q 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 116% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Oct 18New 90-day low: NT$20.30The company is down 16% from its price of NT$24.20 on 17 July 2020. The Taiwanese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 10.0% over the same period.Is New 90 Day High Low • Sep 25New 90-day low: NT$21.00The company is down 18% from its price of NT$25.55 on 24 June 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 1.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、GeneFerm Biotechnology は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TPEX:1796 - アナリストの将来予測と過去の財務データ ( )TWD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2026664166186N/A12/31/2025677297699N/A9/30/20256551685105N/A6/30/2025621-1-124N/A3/31/2025569-8-220N/A12/31/2024521-23-158N/A9/30/2024549-12526N/A6/30/20246123375102N/A3/31/202472886149197N/A12/31/2023794125119190N/A9/30/202378112972186N/A6/30/2023752120-17161N/A3/31/2023674103-14499N/A12/31/202263493-156122N/A9/30/202261793-147121N/A6/30/202258586-84138N/A3/31/202255267-55129N/A12/31/202152257-33112N/A9/30/202147246-4093N/A6/30/202143132-5280N/A3/31/202139322-3262N/A12/31/20203685-2656N/A9/30/2020360-13-2341N/A6/30/2020348-20-3714N/A3/31/2020344-28-491N/A12/31/2019328-28N/A10N/A9/30/2019340-10N/A25N/A6/30/2019341-6N/A39N/A3/31/20193465N/A75N/A12/31/201835710N/A42N/A9/30/20183267N/A39N/A6/30/201833215N/A43N/A3/31/201834925N/A29N/A12/31/201735028N/A61N/A9/30/201737737N/A85N/A6/30/201740648N/A86N/A3/31/201742770N/A118N/A12/31/201645394N/A137N/A9/30/2016459105N/A118N/A6/30/2016450107N/A132N/A3/31/201640578N/A95N/A12/31/201537554N/A69N/A9/30/201532626N/A46N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 1796の予測収益成長が 貯蓄率 ( 1.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 1796の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 1796の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 1796の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 1796の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 1796の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHousehold 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/17 14:49終値2026/07/17 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋GeneFerm Biotechnology Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Upcoming Dividend • Jul 07Upcoming dividend of NT$0.70 per shareEligible shareholders must have bought the stock before 14 July 2026. Payment date: 30 July 2026. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.0%. Lower than top quartile of Taiwanese dividend payers (4.9%). Lower than average of industry peers (5.6%).
Reported Earnings • May 09First quarter 2026 earnings released: NT$0.16 loss per share (vs NT$0.16 profit in 1Q 2025)First quarter 2026 results: NT$0.16 loss per share (down from NT$0.16 profit in 1Q 2025). Revenue: NT$153.2m (down 7.9% from 1Q 2025). Net loss: NT$6.69m (down 203% from profit in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 48 percentage points per year, which is a significant difference in performance.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 23%After last week's 23% share price gain to NT$41.50, the stock trades at a trailing P/E ratio of 59.6x. Average trailing P/E is 16x in the Personal Products industry in Taiwan. Total loss to shareholders of 56% over the past three years.
New Risk • Apr 06New minor risk - Dividend sustainabilityThe dividend is not well covered by earnings. Payout ratio: 101% Dividend yield: 1.7% This is considered a minor risk. Companies that pay out too much of their earnings are at risk of having to reduce or cut their dividend in future. If earnings growth slows or earnings fall, then there may not be enough earnings to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. However, this risk is mitigated by the fact the dividend is covered by cash flows. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 14% per year over the past 5 years. Minor Risks Dividend is not well covered by earnings (101% payout ratio). Market cap is less than US$100m (NT$1.69b market cap, or US$52.7m).
Reported Earnings • Mar 06Full year 2025 earnings released: EPS: NT$0.70 (vs NT$0.54 loss in FY 2024)Full year 2025 results: EPS: NT$0.70 (up from NT$0.54 loss in FY 2024). Revenue: NT$677.1m (up 30% from FY 2024). Net income: NT$28.9m (up NT$51.4m from FY 2024). Profit margin: 4.3% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance.
お知らせ • Mar 06GeneFerm Biotechnology Co., Ltd., Annual General Meeting, Jun 17, 2026GeneFerm Biotechnology Co., Ltd., Annual General Meeting, Jun 17, 2026. Location: no,3, ta li 2nd rd., shanhua district, tainan city Taiwan
Reported Earnings • Nov 07Third quarter 2025 earnings released: EPS: NT$0.14 (vs NT$0.27 loss in 3Q 2024)Third quarter 2025 results: EPS: NT$0.14 (up from NT$0.27 loss in 3Q 2024). Revenue: NT$165.6m (up 26% from 3Q 2024). Net income: NT$5.65m (up NT$16.9m from 3Q 2024). Profit margin: 3.4% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.
New Risk • Oct 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Market cap is less than US$100m (NT$2.16b market cap, or US$70.7m).
Reported Earnings • Aug 09Second quarter 2025 earnings released: EPS: NT$0.02 (vs NT$0.14 loss in 2Q 2024)Second quarter 2025 results: EPS: NT$0.02 (up from NT$0.14 loss in 2Q 2024). Revenue: NT$167.9m (up 45% from 2Q 2024). Net income: NT$898.0k (up NT$6.93m from 2Q 2024). Profit margin: 0.5% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance.
Reported Earnings • May 09First quarter 2025 earnings released: EPS: NT$0.16 (vs NT$0.20 loss in 1Q 2024)First quarter 2025 results: EPS: NT$0.16 (up from NT$0.20 loss in 1Q 2024). Revenue: NT$166.4m (up 41% from 1Q 2024). Net income: NT$6.47m (up NT$14.8m from 1Q 2024). Profit margin: 3.9% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.
Reported Earnings • Mar 15Full year 2024 earnings released: NT$0.54 loss per share (vs NT$3.01 profit in FY 2023)Full year 2024 results: NT$0.54 loss per share (down from NT$3.01 profit in FY 2023). Revenue: NT$521.2m (down 34% from FY 2023). Net loss: NT$22.5m (down 118% from profit in FY 2023). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.
お知らせ • Mar 10GeneFerm Biotechnology Co., Ltd., Annual General Meeting, Jun 19, 2025GeneFerm Biotechnology Co., Ltd., Annual General Meeting, Jun 19, 2025. Location: no,3, ta li 2nd rd., shanhua district, tainan city Taiwan
New Risk • Mar 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Dividend per share is over 18x cash flows per share. Minor Risks Share price has been volatile over the past 3 months (6.0% average weekly change). Market cap is less than US$100m (NT$2.47b market cap, or US$74.9m).
Reported Earnings • Nov 18Third quarter 2024 earnings released: NT$0.27 loss per share (vs NT$0.82 profit in 3Q 2023)Third quarter 2024 results: NT$0.27 loss per share (down from NT$0.82 profit in 3Q 2023). Revenue: NT$131.9m (down 32% from 3Q 2023). Net loss: NT$11.2m (down 133% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.
New Risk • Aug 17New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 5.4% Last year net profit margin: 16% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 250% Cash payout ratio: 111% Minor Risks Profit margins are more than 30% lower than last year (5.4% net profit margin). Market cap is less than US$100m (NT$2.12b market cap, or US$65.7m).
Upcoming Dividend • Jul 03Upcoming dividend of NT$2.00 per shareEligible shareholders must have bought the stock before 10 July 2024. Payment date: 31 July 2024. Payout ratio is on the higher end at 97%, however this is supported by cash flows. Trailing yield: 3.0%. Lower than top quartile of Taiwanese dividend payers (4.2%). Lower than average of industry peers (4.3%).
Valuation Update With 7 Day Price Move • May 21Investor sentiment improves as stock rises 19%After last week's 19% share price gain to NT$66.20, the stock trades at a trailing P/E ratio of 32x. Average trailing P/E is 19x in the Personal Products industry in Taiwan. Total returns to shareholders of 112% over the past three years.
Reported Earnings • May 19First quarter 2024 earnings released: NT$0.20 loss per share (vs NT$0.73 profit in 1Q 2023)First quarter 2024 results: NT$0.20 loss per share (down from NT$0.73 profit in 1Q 2023). Revenue: NT$118.4m (down 36% from 1Q 2023). Net loss: NT$8.31m (down 127% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.
New Risk • Apr 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.1% average weekly change). Market cap is less than US$100m (NT$2.82b market cap, or US$88.2m).
Valuation Update With 7 Day Price Move • Mar 28Investor sentiment improves as stock rises 22%After last week's 22% share price gain to NT$66.90, the stock trades at a trailing P/E ratio of 22.3x. Average trailing P/E is 20x in the Personal Products industry in Taiwan. Total returns to shareholders of 114% over the past three years.
Reported Earnings • Mar 17Full year 2023 earnings released: EPS: NT$3.01 (vs NT$2.26 in FY 2022)Full year 2023 results: EPS: NT$3.01 (up from NT$2.26 in FY 2022). Revenue: NT$793.8m (up 25% from FY 2022). Net income: NT$124.6m (up 33% from FY 2022). Profit margin: 16% (up from 15% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 08GeneFerm Biotechnology Co., Ltd., Annual General Meeting, Jun 19, 2024GeneFerm Biotechnology Co., Ltd., Annual General Meeting, Jun 19, 2024.
New Risk • Oct 18New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.06b (US$94.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
Reported Earnings • Aug 11Second quarter 2023 earnings released: EPS: NT$1.13 (vs NT$0.72 in 2Q 2022)Second quarter 2023 results: EPS: NT$1.13 (up from NT$0.72 in 2Q 2022). Revenue: NT$231.9m (up 51% from 2Q 2022). Net income: NT$46.8m (up 56% from 2Q 2022). Profit margin: 20% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has only increased by 56% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Jun 22Upcoming dividend of NT$1.50 per share at 1.4% yieldEligible shareholders must have bought the stock before 29 June 2023. Payment date: 27 July 2023. Payout ratio is a comfortable 60% but the company is not cash flow positive. Trailing yield: 1.4%. Lower than top quartile of Taiwanese dividend payers (5.5%). Lower than average of industry peers (2.8%).
Valuation Update With 7 Day Price Move • Jun 14Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to NT$112, the stock trades at a trailing P/E ratio of 44.7x. Average trailing P/E is 26x in the Personal Products industry in Taiwan. Total returns to shareholders of 371% over the past three years.
Valuation Update With 7 Day Price Move • May 30Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to NT$127, the stock trades at a trailing P/E ratio of 56.1x. Average trailing P/E is 29x in the Personal Products industry in Taiwan. Total returns to shareholders of 394% over the past three years.
Valuation Update With 7 Day Price Move • May 05Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$139, the stock trades at a trailing P/E ratio of 61.7x. Average trailing P/E is 34x in the Personal Products industry in Taiwan. Total returns to shareholders of 490% over the past three years.
Valuation Update With 7 Day Price Move • Apr 17Investor sentiment improves as stock rises 18%After last week's 18% share price gain to NT$115, the stock trades at a trailing P/E ratio of 51x. Average trailing P/E is 34x in the Personal Products industry in Taiwan. Total returns to shareholders of 381% over the past three years.
Reported Earnings • Mar 22Full year 2022 earnings released: EPS: NT$2.26 (vs NT$1.45 in FY 2021)Full year 2022 results: EPS: NT$2.26 (up from NT$1.45 in FY 2021). Revenue: NT$634.0m (up 21% from FY 2021). Net income: NT$93.5m (up 63% from FY 2021). Profit margin: 15% (up from 11% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has only increased by 68% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Mar 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$100.00, the stock trades at a trailing P/E ratio of 44.4x. Average trailing P/E is 28x in the Personal Products industry in Taiwan. Total returns to shareholders of 295% over the past three years.
Valuation Update With 7 Day Price Move • Feb 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$82.70, the stock trades at a trailing P/E ratio of 36.7x. Average trailing P/E is 30x in the Personal Products industry in Taiwan. Total returns to shareholders of 215% over the past three years.
Valuation Update With 7 Day Price Move • Dec 19Investor sentiment improved over the past weekAfter last week's 17% share price gain to NT$65.60, the stock trades at a trailing P/E ratio of 29.1x. Average trailing P/E is 28x in the Personal Products industry in Taiwan. Total returns to shareholders of 121% over the past three years.
Reported Earnings • Nov 13Third quarter 2022 earnings released: EPS: NT$0.61 (vs NT$0.45 in 3Q 2021)Third quarter 2022 results: EPS: NT$0.61 (up from NT$0.45 in 3Q 2021). Revenue: NT$166.1m (up 24% from 3Q 2021). Net income: NT$25.5m (up 40% from 3Q 2021). Profit margin: 15% (up from 14% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Aug 26Investor sentiment improved over the past weekAfter last week's 17% share price gain to NT$54.80, the stock trades at a trailing P/E ratio of 26.4x. Average trailing P/E is 22x in the Personal Products industry in Taiwan. Total returns to shareholders of 73% over the past three years.
Upcoming Dividend • Jun 16Upcoming dividend of NT$1.00 per shareEligible shareholders must have bought the stock before 23 June 2022. Payment date: 15 July 2022. Payout ratio is a comfortable 5.1% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of Taiwanese dividend payers (6.0%). Lower than average of industry peers (4.0%).
Reported Earnings • May 09First quarter 2022 earnings released: EPS: NT$0.50 (vs NT$0.31 in 1Q 2021)First quarter 2022 results: EPS: NT$0.50 (up from NT$0.31 in 1Q 2021). Revenue: NT$143.9m (up 26% from 1Q 2021). Net income: NT$20.5m (up 81% from 1Q 2021). Profit margin: 14% (up from 10.0% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Nov 11Third quarter 2021 earnings released: EPS NT$0.45 (vs NT$0.15 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: NT$133.9m (up 44% from 3Q 2020). Net income: NT$18.2m (up 340% from 3Q 2020). Profit margin: 14% (up from 4.5% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Oct 12Investor sentiment improved over the past weekAfter last week's 20% share price gain to NT$42.00, the stock trades at a trailing P/E ratio of 53.6x. Average trailing P/E is 15x in the Personal Products industry in Taiwan. Total returns to shareholders of 1.9% over the past three years.
Upcoming Dividend • Jul 15Upcoming dividend of NT$0.083 per shareEligible shareholders must have bought the stock before 22 July 2021. Payment date: 12 August 2021. Trailing yield: 0.2%. Lower than top quartile of Taiwanese dividend payers (5.0%). Lower than average of industry peers (3.8%).
Reported Earnings • May 09First quarter 2021 earnings released: EPS NT$0.31 (vs NT$0.20 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: NT$113.9m (up 28% from 1Q 2020). Net income: NT$11.3m (up NT$17.0m from 1Q 2020). Profit margin: 10.0% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.
分析記事 • Apr 16GeneFerm Biotechnology (GTSM:1796) Takes On Some Risk With Its Use Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Mar 29Full year 2020 earnings released: EPS NT$0.16 (vs NT$0.99 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$368.3m (up 12% from FY 2019). Net income: NT$4.53m (up NT$32.1m from FY 2019). Profit margin: 1.2% (up from net loss in FY 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.
分析記事 • Mar 12Will GeneFerm Biotechnology (GTSM:1796) Multiply In Value Going Forward?If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Reported Earnings • Mar 12Full year 2020 earnings released: EPS NT$0.16 (vs NT$0.99 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$368.3m (up 12% from FY 2019). Net income: NT$4.53m (up NT$32.1m from FY 2019). Profit margin: 1.2% (up from net loss in FY 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 97% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
お知らせ • Mar 11GeneFerm Biotechnology Co., Ltd., Annual General Meeting, May 25, 2021GeneFerm Biotechnology Co., Ltd., Annual General Meeting, May 25, 2021.
Is New 90 Day High Low • Jan 13New 90-day high: NT$31.80The company is up 57% from its price of NT$20.30 on 16 October 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is down 7.0% over the same period.
分析記事 • Dec 21Does GeneFerm Biotechnology (GTSM:1796) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Is New 90 Day High Low • Nov 16New 90-day high: NT$25.50The company is up 7.0% from its price of NT$23.80 on 18 August 2020. The Taiwanese market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is down 15% over the same period.
Reported Earnings • Nov 08Third quarter 2020 earnings released: EPS NT$0.14The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$92.9m (up 15% from 3Q 2019). Net income: NT$4.14m (up NT$6.50m from 3Q 2019). Profit margin: 4.5% (up from net loss in 3Q 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 116% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Oct 18New 90-day low: NT$20.30The company is down 16% from its price of NT$24.20 on 17 July 2020. The Taiwanese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 10.0% over the same period.
Is New 90 Day High Low • Sep 25New 90-day low: NT$21.00The company is down 18% from its price of NT$25.55 on 24 June 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 1.0% over the same period.